FACET SYNDROME

Download full text PDF
Issue: 
10
Year: 
2015

O. Davydov (1), Candidate of Medical Sciences; L. Pavlova (2); E. Zhukov (2) 1 -Research and Practical Psychoneurology Center, Moscow Healthcare Department 2 -Family medical center IMMA, Moscow

Facet syndrome occupies one of the leading places among the causes of back pains. In spite of diagnostic complexities, comprehensive clinical and diagnostic examination helps establish this diagnosis and purposeful and multimodal therapy for this syndrome, which incorporates nonsteroidal antiinflammatory drugs as first-line agents, nerve blocks with local anesthetics and corticosteroids, radiofrequency denervation, and facetoplasty, allows the leading manifestation of the disease (pain syndrome) to be completely alleviated in most cases.
Keywords: 
back pain
facet syndrome
nonsteroidal anti-inflammatory drugs

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. – 2015; pii: S0140-6736(15)60692-4
  2. Matrosov D.N., Galushko E.A., Erdes Sh.F. Epidemiologija bolej v nizh nej chasti spiny v ambulatornoj praktike // Bol'. – 2009; 4 (25): 23–8.
  3. Koes B., van Tulder M., Lin C. et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care // Eur. Spine J. – 2010; 19 (12): 2075–94.
  4. Manchikanti L., Singh V., Pampati V. et al. Evaluation of the relative contributions of various structures in chronic low back pain // Pain Physician. – 2001; 4 (4): 308–16.
  5. Schwarzer A., Wang S., Bogduk N. et al. Prevalence and clinical features of lumbar zygapophysial joint pain: A study in an Australian population with chronic low back pain // Am. Rheum. Dis. – 1995; 54: 100–6.
  6. Manchikanti L., Pampati V., Fellows B. et al. Prevalence of lumbar facet joint pain in chronic low back pain // Pain Physician. – 1999; 2: 59–64.
  7. Cohen S., Raja S. Pathogenesis, diagnosis, and treatment of lumbar 7. zygapophyseal (facet) joint pain // Anesthesiology. – 2007; 106: 591–614.
  8. Bogduk N. Lumbar Facet Syndrome, In Pain Management. Ed. by S. Waldman, W. Saunders / Philadelphia, 2007; r. 769–76.
  9. Kalichman L. et al. Facet joint osteoarthritis and low back pain in the community-based population // Spine (Phila Pa 1976). – 2008; 33: 2560–5.
  10. Beresford Z., Kendall R., Willick S. Lumbar facet syndromes // Curr. Sports Med. Rep. – 2010; 9 (1): 50–6.
  11. Varlotta G., Lefkowitz T., Schweitzer M. et al. The lumbar facet joint: a review of current knowledge: part 1: anatomy, biomechanics, and grading // Skeletal. Radiol. – 2011; 40 (1): 13–23.
  12. Igarashi A., Kikuchi S., Konno S. et al. Inflammatory cytokines released from the facet joint tissue in degenerative lumbar spinal disorders // Spine (Phila Pa 1976). – 2004; 29 (19): 2091–5.
  13. Genevay S., Finckh A., Payer M. et al. Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc // Spine (Phila Pa 1976). – 2008; 33 (19): 2041–6.vanKleef M. et al.
  14. Pain originating from the lumbar facet joints // Pain 14. Pract. – 2010; 10: 459–69.
  15. Gellhorn A., Katz J., Suri P. Osteoarthritis of the spine: the facet joints // Nat. 15. Rev. Rheumatol. – 2013; 9 (4): 216–24.
  16. Dwyer A., Aprill C., Bogduk N. Cervical zygapophyseal joint pain patterns. I: A study in normal volunteers // Spine (Phila Pa 1976). – 1990; 15 (6): 453–7
  17. Revel M., Poiraudeau S., Auleley G. et al. Capacity of the clinical picture to characterize low back pain relieved by facet joint anesthesia: Proposed criteria to identify patients with painful facet joints // Spine. – 1998; 23 (18): 1972–6.
  18. Podchufarova E.V. Bol' v spine. V kn.: Bol' (prakticheskoe rukovodstvo dlja vrachej). Pod red. N.N. Jahno, M.L. Kukushkina / M.: Izdatel'stvo RAMN, 2011; s. 230–97.
  19. Vorob'eva O.V. Fasetochnyj sindrom kak prichina boli v spine // Effektivnaja farmakoterapija. – 2012; 1: 4–9.
  20. Chou R., Huffman L. American Pain Society; American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain ociety / American College of Physicians clinical practice guideline // Ann. Intern. Med. – 2007; 147 (7): 505–14.
  21. Karateev A.E., Nasonov E.L., Jahno N.N. i dr. Klinicheskie rekomenda tsii «Ratsional'noe primenenie nesteroidnyh protivovospalitel'nyh pre-paratov (NPVP) v klinicheskoj praktike» // Sovremennaja revmatologija. – 2015; 1: 4–24
  22. Habirov F.A., Habirova Ju.F. Bol' v shee i spine. Ruk. dlja vrachej / Kazan': Meditsina, 2014; 503 s.
  23. Amelin A.V., Davydov O.S. Farmakoterapija boli. V kn.: Bol' (prakti cheskoe rukovodstvo dlja vrachej). Pod red. N.N. Jahno, M.L. Kukushkina / M.: Izdatel'stvo RAMN, 2011; s. 89–144.
  24. De Vecchis R., Baldi C., Di Biase G. et al. Cardiovascular risk associated with celecoxib or etoricoxib: ameta-analysis of randomized controlled trials which adopted comparison withplacebo or naproxen // Minerva Cardioangiol. – 2014; 62 (6): 437–48.
  25. Ramey D., Watson D., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis // Curr. Med. Res. Opin. – 2005; 21 (5): 715–22.
  26. Jensen M., Schnitzer T., Wang H. et al. Sensitivity of single-domain versus multiple-domain outcome measures to identify responders in chronic low-back pain: pooled analysis of 2 placebo-controlledtrials of etoricoxib // Clin. J. Pain. – 2012; 28 (1): 1–7.
  27. Zerbini C., Ozturk Z., Grifka J. et al. Efficacy of etoricoxib 60mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized,double-blind study // Curr. Med. Res. Opin. – 2005; 21 (12): 2037–49.
  28. Birbara C., Puopolo A., Munoz D. et al. Treatment of chronic low back pain withetoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial // J. Pain. – 2003; 4 (6): 307–15.
  29. Sheldon E., Bird S., Smugar S. et al. Correlation of measures ofpain function, and overall response: results pooled from two identical studiesof etoricoxib in chronic low back pain // Spine (Phila Pa 1976). – 2008; 33 (5): 533–8.
  30. Moore R., Moore O., Derry S. et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice // Ann. Rheum. Dis. – 2010; 69: 374–9.
  31. Malmstrom K., Sapre A., Couglin H. et al. Etoricoxib in acute pain associated with dental surgery: a randomized,double-blind, placebo- and active comparator-controlled dose-ranging study // Clin. Ther. – 2004; 26 (5): 667–79.
  32. Auvinet B., Ziller R., Appelboom T. et al. Comparison of the onset 32. andintensity of action of intramuscular meloxicam and oral meloxicam in patientswith acute sciatica // Clin. Ther. – 1995; 17 (6): 1078–98.
  33. Chou R., Huffman L. American Pain Society; American College of Physicians. 33. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline // Ann. Intern. Med. – 2007; 147 (7): 492–504.
  34. Chou R., Hashimoto R., Friedly J. et al. Pain Management Injection 34. Therapies for Low Back Pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Mar. AHRQ Technology Assessments.